 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- | succinobucol (succinobucol) / Merck (MSD)
Journal: PLGA Nanoparticles Containing VCAM-1 Inhibitor Succinobucol and Chemotherapeutic Doxorubicin as Therapy against Primary Tumors and Their Lung Metastases. (Pubmed Central) - Feb 25, 2023
Additionally, the in vivo experiments showed that Co-NPs could efficiently suppress not only primary melanoma but also its lung metastases. In conclusion, PLGA nanoparticles containing VCAM-1 inhibitor Suc and chemotherapeutic Dox as therapy against primary tumors and their lung metastases provides a promising drug delivery strategy for the treatment of metastatic malignant tumors.
- || Retrospective data, Review, Journal: Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials. (Pubmed Central) - Jul 5, 2022
The findings will be disseminated through a peer-reviewed journal. CRD42022303289.
- |||| succinobucol (succinobucol) / Merck (MSD)
Clinical: "It's fine to ask if people are vaccinated and to make decisions based on your comfort level." @TuftsMedSchool Interim Dean & #TuftsMC Infectious Disease Specialist Dr. Helen Boucher talks holiday gatherings with @MAGIC1067 Listen: https://t.co/wXX6ZcLCEI @hboucher3 (Twitter) - Nov 23, 2021
- | succinobucol (succinobucol) / Merck (MSD)
Journal: Preferential Targeting Cerebral Ischemic Lesions with Cancer Cell-Inspired Nanovehicle for Ischemic Stroke Treatment. (Pubmed Central) - Jun 26, 2021
Inspired by the intriguing blood-brain barrier (BBB)-penetrating ability of 4T1 cancer cells upon their brain metastasis, we herein designed a promising biomimetic nanoplatform by camouflaging a succinobucol-loaded pH-sensitive polymeric nanovehicle with a 4T1 cell membrane (MPP/SCB), aiming to promote the preferential targeting of cerebral ischemic lesions to attenuate the ischemia/reperfusion injury...Moreover, MPP/SCB produced notable enhancement of microvascular reperfusion in the ischemic hemisphere, resulting in a 69.9% reduction of infarct volume and showing remarkable neuroprotective effects of tMCAO rats, which was superior to the counterpart uncamouflaged nanovehicles (PP/SCB). Therefore, this design provides a promising nanoplatform to target the cerebral ischemic lesions for ischemic stroke therapy.
- succinobucol (succinobucol) / Merck (MSD)
[VIRTUAL] LIPID-INDUCED ENDOTHELIAL VASCULAR CELL ADHESION MOLECULE 1 PROMOTES NASH PATHOGENESIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_145;
Lipotoxic stress enhances the expression of LSEC VCAM-1 mainly via an MLK3-dependent mechanism. Inhibition of VCAM-1 is salutary in murine NASH, and might serve as a potential therapeutic strategy for human NASH.
- succinobucol (succinobucol) / Merck (MSD)
LIPID-INDUCED ENDOTHELIAL VASCULAR CELL ADHESION MOLECULE 1 PLAYS A PIVOTAL ROLE IN NASH PATHOGENESIS () - May 4, 2020 - Abstract #DDW2020DDW_3869;
Lipotoxic stress enhances the expression of LSEC VCAM-1 mainly through a MAPK/NF-κB pathway. Inhibition of VCAM-1 might be a potential anti-inflammatory therapeutic strategy for NASH.